PHENYLBUTYRATE CO-DEVELOPMENT AND SUBLICENSE AGREEMENT BY AND AMONG BRIDGE THERAPEUTIC PRODUCTS, INC AND BRIDGE ONCOLOGY PRODUCTS, INC.Sublicense Agreement • July 19th, 2006 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations • New York
THIS AGREEMENT (the “Agreement”), is made and effective as of February 16, 2005 (the “Effective Date”), by and between Bridge Therapeutic Products Inc. (“BTP”) and Bridge Oncology Products Inc. (“BOP” and, together with BTP, the “Parties”).
CONFIDENTIALITY TREATMENT REQUESTEDResearch Collaboration and License Agreement • July 19th, 2006 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations • New York
NOW THEREFORE, for good and valuable consideration, included the premises and mutual promises herein, IT IS AGREED as follows:
ContractPatent and Know-How Assignment and License Option Agreement • July 19th, 2006 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations • London
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT IS REQUESTED AND IS NOTED WITH “[CONFIDENTIAL TREATMENT REQUESTED].” AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
ContractPatent and Know-How Exclusive Sublicense Agreement • July 19th, 2006 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations • California
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT IS REQUESTED AND IS NOTED WITH “[CONFIDENTIAL TREATMENT REQUESTED].” AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
